Lifecore Biomedical (LFCR) Competitors $6.34 +0.09 (+1.44%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LFCR vs. MLYS, ETNB, COLL, DYN, ELVN, RCUS, CMRX, CDMO, SYRE, and NTLAShould you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include Mineralys Therapeutics (MLYS), 89bio (ETNB), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Arcus Biosciences (RCUS), Chimerix (CMRX), Avid Bioservices (CDMO), Spyre Therapeutics (SYRE), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry. Lifecore Biomedical vs. Mineralys Therapeutics 89bio Collegium Pharmaceutical Dyne Therapeutics Enliven Therapeutics Arcus Biosciences Chimerix Avid Bioservices Spyre Therapeutics Intellia Therapeutics Lifecore Biomedical (NASDAQ:LFCR) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability. Which has preferable valuation and earnings, LFCR or MLYS? Lifecore Biomedical has higher revenue and earnings than Mineralys Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifecore Biomedical$130.86M1.72$12.01M-$1.45-4.19Mineralys TherapeuticsN/AN/A-$177.81M-$3.64-3.62 Is LFCR or MLYS more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -12.52%. Mineralys Therapeutics' return on equity of -67.97% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Lifecore Biomedical-12.52% -315.23% -12.74% Mineralys Therapeutics N/A -67.97%-62.40% Does the MarketBeat Community favor LFCR or MLYS? Mineralys Therapeutics received 16 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 25.00% of users gave Lifecore Biomedical an outperform vote. CompanyUnderperformOutperformLifecore BiomedicalOutperform Votes325.00% Underperform Votes975.00% Mineralys TherapeuticsOutperform Votes19100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in LFCR or MLYS? 83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 32.2% of Lifecore Biomedical shares are owned by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor LFCR or MLYS? In the previous week, Mineralys Therapeutics had 7 more articles in the media than Lifecore Biomedical. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 3 mentions for Lifecore Biomedical. Mineralys Therapeutics' average media sentiment score of 0.86 beat Lifecore Biomedical's score of 0.30 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mineralys Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend LFCR or MLYS? Lifecore Biomedical presently has a consensus target price of $8.00, suggesting a potential upside of 31.80%. Mineralys Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 150.19%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Mineralys Therapeutics is more favorable than Lifecore Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Mineralys Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, LFCR or MLYS? Lifecore Biomedical has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.39, meaning that its stock price is 139% less volatile than the S&P 500. SummaryMineralys Therapeutics beats Lifecore Biomedical on 12 of the 17 factors compared between the two stocks. Remove Ads Get Lifecore Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LFCR vs. The Competition Export to ExcelMetricLifecore BiomedicalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$224.74M$6.28B$5.30B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-10.846.7321.6917.67Price / Sales1.72221.51371.5292.57Price / CashN/A65.6738.1534.64Price / Book16.415.776.373.94Net Income$12.01M$142.23M$3.20B$247.37M7 Day Performance-2.57%3.19%1.91%0.64%1 Month Performance-6.18%-13.67%-9.32%-6.98%1 Year Performance-7.19%-12.37%9.64%-0.32% Lifecore Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LFCRLifecore Biomedical1.828 of 5 stars$6.34+1.4%$8.00+26.2%+0.0%$234.74M$130.86M-11.32690MLYSMineralys Therapeutics2.3683 of 5 stars$13.92+3.9%$33.00+137.1%+12.5%$873.97MN/A-3.8228Insider TradeShort Interest ↑ETNB89bio2.5898 of 5 stars$5.92+7.1%$27.56+365.5%-36.2%$864.23MN/A-2.0340Short Interest ↑COLLCollegium Pharmaceutical4.1502 of 5 stars$26.73+1.6%$43.60+63.1%-22.8%$858.89M$631.45M11.52210Gap DownDYNDyne Therapeutics3.5776 of 5 stars$7.47+6.1%$47.46+535.4%-69.1%$845.01MN/A-2.10100ELVNEnliven Therapeutics2.5613 of 5 stars$17.19+4.1%$40.33+134.6%-14.5%$842.38MN/A-9.0550Gap DownRCUSArcus Biosciences2.2837 of 5 stars$7.67-6.2%$30.25+294.4%-50.9%$806.41M$258M-2.43500Gap DownCMRXChimerix2.7612 of 5 stars$8.54+0.2%$8.53-0.1%+834.8%$801.09M$212,000.00-9.0990Analyst ForecastPositive NewsCDMOAvid Bioservices0.8042 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320Upcoming EarningsHigh Trading VolumeSYRESpyre Therapeutics1.6655 of 5 stars$13.02+6.5%$49.57+280.7%-65.8%$784.55M$890,000.00-1.74100Gap DownNTLAIntellia Therapeutics4.3213 of 5 stars$7.50+1.2%$37.56+400.7%-67.9%$776.38M$57.88M-1.38600Gap Down Remove Ads Related Companies and Tools Related Companies Mineralys Therapeutics Competitors 89bio Competitors Collegium Pharmaceutical Competitors Dyne Therapeutics Competitors Enliven Therapeutics Competitors Arcus Biosciences Competitors Chimerix Competitors Avid Bioservices Competitors Spyre Therapeutics Competitors Intellia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LFCR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lifecore Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LFCR Stock Free LFCR Stock Alerts